Having discovered that the GSH/GPX4 antioxidant response limits EZH2i antitumor effects in ACC, gives the possibility to turn a limitation into a therapeutic advantage, using EZH2i with ferroptosis inducers as a combination strategy. Here, GPX4 is linked to adrenal cortex carcinoma.